Berglind Johannsdottir

Karolinska University Hospital

Papers

1

Total Citations

19

H-Index

1

About

Berglind Johannsdottir is a leading surgical oncologist whose work centers on testicular cancer, with a particular focus on refining treatment strategies to reduce long-term toxicity. Her major contribution lies in pioneering the use of primary retroperitoneal lymph node dissection (RPLND) as an alternative to standard cytotoxic therapy for low-volume metastatic seminoma. In her landmark 2024 study, published as part of the Swedish Norwegian Testicular Cancer Group, she demonstrated that RPLND can achieve strong oncological control while sparing patients the lifelong cardiovascular and metabolic risks associated with chemotherapy or radiation. This population-based cohort study, already cited 19 times, has reshaped clinical thinking by offering a viable surgical path to de-escalate treatment. Johannsdottir’s work directly addresses an unmet need in survivorship care, positioning her as a key voice in the movement toward personalized, morbidity-sparing cancer management. Her research continues to influence urologic oncology guidelines and inspires a new generation of surgeons to challenge conventional cytotoxic paradigms.

Research Focus

Key Achievements

1
H-Index
1
Papers
19
Total Citations
19
Avg Citations/Paper
🏆 Most Cited Paper
Primary Retroperitoneal Lymph Node Dissection as Treatment for Low-volume Metastatic Seminoma in a Population-based Cohort: The Swedish Norwegian Testicular Cancer Group Experience
19 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 20
🏛 Institutions: Karolinska University Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago